Drugs / NSC 683472 gp100: 209-217(210M)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00580060 | Dec 2003 → Jun 2011 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSC 683472 gp100: 209-217(210M) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580060 ↗ |
| Modality | Peptide | “both peptides subcutaneously” NCT00580060 ↗ |
| Route | Subcutaneous | “both peptides subcutaneously” NCT00580060 ↗ |